



ORIGINAL ARTICLE

Platelet activities in pregnant women living with Human Immunodeficiency Virus on HAART in Lagos, Nigeria

Olufemi David Olaniyi¹, Tesleemah Oluwakemi Davies-Folorunsho¹, Abdulwaheed Adewale Ademosun¹, Nuryan Abdulganiyu¹, Omoruyi Pius Omosigbo, Matthew Folaranmi Olaniyan¹ And Musa Abidemi Muhibi^{1*}

¹Department of Medical Laboratory Science, Faculty of Applied Health Sciences, Edo State University, Uzairue, Edo State

Email:
muhibimm@gmail.com

Submitted: 21-02-2023
Accepted: 19-03-2023:
Published: 31-03-2023

ABSTRACT

Introduction: Thrombocytopenia due to insufficient thromboxane A₂ activation has been an independent predictor associated with bleeding in some pregnant women living with HIV. More so, the elevation in the systemic vasoconstriction by the abnormal activation of platelets through thromboxane A₂ is a multi-system disorder during pregnancy resulting in maternal hypertension which is one of the major underlying pathophysiological occurrences in women with preeclampsia.

Materials and Method: A cross-sectional, descriptive study to determine platelet activities in pregnant women living with Human Immunodeficiency Virus on HAART residing in Lagos State, was carried out. A total of 80 samples were collected; 40 from pregnant women on HAART (group A), 20 samples from HIV negative pregnant women (group B) and 20 from non-pregnant HIV positive women on HAART (group C). The samples were analyzed using automated haematology analyzer (MIDRAY BC 10), platelets morphology was reviewed from blood films stained by Leishman stain and thromboxane A₂ was quantified using standard ELISA technique. Data was analyzed with SPSS version 23.0. Values were considered significantly different at $P < 0.05$.

Results: The platelets count results revealed the mean \pm standard error of mean (SEM) in group A, group B and group C as 236.27 ± 11.40 , 227.26 ± 16.44 and 246.21 ± 21.54 respectively ($p = 0.743$). The Platelet distribution width (PDW) revealed the mean \pm SEM in group A, group B and group C as 13.50 ± 0.42 , 13.36 ± 0.53 and 12.56 ± 0.52 ($p = 0.390$). As for mean platelet volume (MPV), the mean \pm SEM for group A,

group B and group C were 12.36 ± 1.96 , 10.71 ± 0.37 , and 10.45 ± 1.78 respectively ($p = 0.671$). The mean \pm SEM of thromboxane A₂ in group A, group B and group C were 367.65 ± 37.74 , 135.85 ± 51.69 and 276.10 ± 50.90 ($p = 0.02$).

Conclusion and Recommendation: This study showed platelet aggregation in group A, group B and group C were 7.5%, 0%, and 2%; and this could be one of the suggestive factors in the increase in coagulation activities found in pregnancy. Thromboxane A₂ level reflects a recent activation of platelets, thus it serves as a good biomarker. It is recommended that research be conducted to establish reference ranges of Thromboxane A₂ for categories of normal individuals, including pregnant women in Lagos while attention should be paid to platelet activity studies in the Prevention of Mother to Child Transmission (PMTCT) programmes, to prevent mortality of participants on account of platelet aberrations.

Keywords: HIV, HAART, PMTCT, Platelet Distribution Width, Thromboxane A₂

INTRODUCTION

Most women in developing countries like Nigeria experience severe or other life threatening health issues during pregnancy or childbirth. These complications during pregnancy and childbirth resulted to an increase in mortality and morbidity compared to other reproductive health problems in African countries generally.

The rate of maternal mortality in Nigeria between 1999 and 2015 is among the highest in the world ranking the 10th out of 183 countries. The maternal mortality ratio is 1:100, with an estimated 59,000 annual maternal deaths making Nigeria the leading contributor to the maternal death in Africa.

The prevalence HIV infection in Nigeria is around 3.6% which is third largest number of HIV infected people in the world. According to the report released by the Government of

Nigeria, the national HIV prevalence in Nigeria is 1.4% among adults aged 15–49 years. Previous estimates had indicated a national HIV prevalence of 2.8%. In spite of Nigeria's national HIV prevalence rate of 1.4% among adults aged 15–49 years, women aged 15–49 years (1.9%) are more than twice as likely to be living with HIV than men (0.9%). The difference in HIV prevalence between women and men is greatest among younger adults, with young women aged 20–24 years more than three times as likely to be living with HIV as young men in the same age group. The epidemic of HIV in Nigeria had shown that pregnant women are more vulnerable and adversely affected due to the compromised state of their immunity.

Many studies have shown that pregnant women living with HIV have between 2–10 times increase risk of mortality than uninfected

pregnant women⁷. There is a strong evidence that there is more risk in pregnant women in low-income countries in sub-Saharan Africa with significantly higher probability of maternal and child deaths.

The platelets multifunctional roles can also be associated with maternal and infant mortality rates. Thrombocytopenia due to insufficient thromboxane A₂ activation has been an independent predictor associated with bleeding in pregnant women living with HIV.

The pathway of platelets production during haematopoiesis in a sub-process is called thrombopoiesis. Thrombopoiesis takes place in common myeloid progenitor cells in the bone marrow, starting with megakaryoblast, which first differentiate into promegakaryocytes and then into megakaryocytes. Megakaryocyte and platelet production is regulated by a hormone called thrombopoietin, which is produced by the liver and kidneys, and the process operates a feedback mechanism. The proplatelets then proliferates into hundreds of platelets that circulate in the bloodstream, while the remaining nucleus of the ruptured megakaryocyte is consumed by macrophages. Each megakaryocyte produces between 5,000 and 10,000 platelets before its cellular components are fully depleted. Altogether, around 10¹¹ platelets are produced each day in a healthy adult. The average lifespan of a platelet is just 5 to 10 days. The destruction of old platelets by macrophage phagocytosis takes place in the spleen and by Kupffer cells in the liver. Large volume of platelets are stored in the spleen as a reserve, which is released on feedback by sympathetically-induced splenic muscle contractions during severe injury. Thromboxane A₂ (TxA₂) belongs to the family of lipids known as eicosanoids, which are metabolites of arachidonic acid. They are produced by the sequential action of three enzymes namely; phospholipase A₂, Cyclooxygenase (COX) and TxA₂ Synthase (

TXAS). TxA₂ is described as being majorly released from platelets activities, with some minute secretions from endothelial cells, macrophages and neutrophils. Thromboxane A₂ (TXA₂) is known to be a potent stimulator of platelet activation, aggregation, and vascular constriction. Thromboxane A₂ exhibits its pathophysiological activity by binding to a G-protein-coupled specific receptor, the thromboxane prostanoid (TP) receptor. TXA₂ may also act as a potent angiogenic stimulator directly as well as indirectly by supplying cytokines such as pro-angiogenic factors upon platelet aggregation. TXA₂ may enhance angiogenesis by enhancing the interactions between platelets and endothelial cells. In HIV-infected individuals, there is a direct HIV binding and interactions with platelets leading to platelet hyper-activation, micro-particle formation, platelet reactivity and aggregation to the blood vessels, immune cells and also erythrocytes. The aim of this study was to determine platelet activities in pregnant women living with HIV on HAART in Lagos State.

Materials and Methods

Study Design

This was a cross-sectional, descriptive study of HIV positive pregnant women on HAART attending ante natal clinics in Tertiary health facilities in Lagos State.

Study Area

Geographically, Lagos State is lying approximately on longitude 3° 23' 40.81"E and latitude 6° 27' 14.65"N, located on the South-Western part of Nigeria. The population of Lagos was estimated to be over 21 million in 2016 and is the largest city of Africa.

Duration of Study

This study was conducted between November 2022 and February 2023.

Sample Size

A total of 80 samples from three different groups, viz: 40 pregnant women on prevention of mother to child transmission (PMTCT), 20 HIV negative pregnant women and 20 HIV positive women (not pregnant) of child bearing were recruited.

Sample Collection

A volume of 5mls of sample was collected into Ethylenediamine tetraacetic acid (EDTA) bottle from each participant.

Laboratory Procedure

Each sample collected was transported immediately to the College of Medicine, Lagos State University, O&G Research Laboratory Department (LASUCOM-LASUTH) under one hour of collection, without exposing the sample to cold or extreme heat. Full blood count was done immediately with auto analyzer BC-10. The samples were then spun at 1000rpm for 15minutes according to manufacturer's instruction to harvest plasma samples which were stored at -20°c until used for Thromboxane A_2 Assay. Thromboxane A_2 was assayed for, using ELISA technique in which polystyrene microwells pre-coated with monoclonal antibodies specific to Thromboxane A_2 was employed. Participant's plasma sample was added to the microwell together with a second antibody conjugated enzyme and directed against the Thromboxane A_2 . During incubation, the specific complex formed was captured on the solid phase. After washing to remove sample plasma proteins and unbound HRP-conjugate antibody, chromogen solutions containing tetramethylbenzidine (TMB) and urea peroxide were added to the wells. In presence of the antibody-antigen-antibody "sandwich" immunocomplex, the colorless TMB Solution are hydrolyzed by the bound HRP-conjugate antibody to a blue-colored product. The blue

color turns yellow after stopping the reaction with acid. The amount of color intensity was measured spectrophotometrically with ELISA plate reader and it is proportional to the amount of Thromboxane A_2 captured in the wells, and to its amount in the sample respectively.

Data Analysis: Data was analyzed using SPSS 23.0 statistical package where ANOVA was used as the tool for comparison. P-value of < 0.05 was considered as evidence of significant statistical difference.

Results

The correlations of Thromboxane A_2 in women on PMTCT with Platelet, PDW and Age (- 0.049, 0.061, and 0.098) were not significant ($P > 0.05$). Details are as depicted in Table 1. The correlation of Thromboxane A_2 with Platelet, PDW and Age were equally insignificant in non-pregnant women on HAART and HIV negative women ($P > 0.05$). Details of the correlation coefficients and p values are depicted in Tables 2 and 3.

However, thromboxane A_2 are significantly elevated in pregnant women on HAART ($367.65 \pm 37.74 \text{pg/mL}$) and relatively elevated in non-pregnant women on HAART too ($276.10 \pm 50.90 \text{pg/mL}$) as against HIV-negative subjects where $135.85 \pm 51.69 \text{pg/mL}$ was recorded ($p=0.02$). The details of intergroups comparison with ANOVA is presented in Table 4.

Table 1. Correlation of Thromboxane A₂ in HIV positive pregnant women on HAART with other platelet parameters and age.

	r	p
Thromboxane / PLT	- 0.049	0.766
Thromboxane / PDW	0.061	0.709
Thromboxane / AGE	0.098	0.548

r = Pearson correlation coefficient
 - r value =Inverse relationship

* P significant @ p <0.05
 + r value =Direct relationship

Table 2. Correlation of Thromboxane A₂ in HIV negative pregnant women with other platelet parameters and age.

	r	p
Thromboxane / PLT	- 0.151	0.525
Thromboxane / PDW	- 0.028	0.908
Thromboxane / AGE	- 0.130	0.586

r =Pearson correlation coefficient
 - r value =Inverse relationship

* P significant @ P < 0.05
 + r value =Direct relationship

Table 2. Correlation of Thromboxane A₂ in HIV negative pregnant women with other platelet parameters and age.

	r	p
Thrombo xane / PLT	- 0.151	0.525
Thrombo xane / PDW	- 0.028	0.908
Thrombo xane / AGE	- 0.130	0.586

r =Pearson correlation coefficient * P significant @ P < 0.05
 - r value =Inverse relationship + r value =Direct relationship

Table 3. Correlation of Thromboxane A₂ in HIV positive, non-pregnantwomen on HARRT with other platelet parameters and age.

	r	p
Thrombo xane / PLT	0.116	0.626
Thrombo xane / PDW	0.233	0.322
Thrombo xane / AGE	0.108	0.651

r =Pearson correlation coefficient * P significant @ P < 0.05
 - r value =Inverse relationship + r value =Direct relationship

Table 4. Comparison of the platelet parameters across the groups (ANOVA)

	Group A	Group B	Group C	f	p
PLT ($10^9/L$)	236.27±11.40	227.26±16.44	246.96±21.54	0.311	0.943
PDW (%)	13.50±0.42	13.36±0.53	12.56±0.52	0.952	0.390
TXA2(pg/mL)	367.65±37.74	135.85±51.69	276.10±50.90	6.557	0.02
Age(years)	32.65±0.72	31.30±0.84	33.25±1.23	0.938	0.396

P significant @ $P < 0.05$

Discussion

Several studies on platelet activities had been conducted. This study had shown that there is no significant statistically difference in the mean of platelet count in pregnant women in cases (group A) and controls (group B and group C) with a reference range of $100 \times 10^9/L$ - $400 \times 10^9/L$. This is in line with the study conducted by Babah *et al* in a cross sectional at University of Lagos Teaching Hospital (LUTH) with the mean of $205.48 \times 10^9/L$ in pregnant women and $234.75 \times 10^9/L$ in non pregnant women¹⁹. The study had shown no significant difference in PDW which was attributed to blood volume expansion that occurs during pregnancy and suggested that the increase in PDW in pregnancy might contribute slightly to the hypercoagulability associated with pregnancy. In the study reported by Tesfay *et al*,²⁰ there was an increase in mean platelet count in the pregnant women compared to the non-pregnant group ($226.54 \times 10^9/L$ versus $214.95 \times 10^9/L$) but no significant difference in the PDW ($p > 0.05$). A significant increase in the concentration of thromboxane A_2 was observed in HIV positive pregnant women on HAART with a reference range of 292.17pg/mL - 443.13pgpg/mL compared to

HIV negative women and non-pregnant HIV positive women ($P = 0.02$). This may be attributed to hyper-responsiveness of platelets activities in pregnant women on HAART.

CONCLUSION

This study had shown thromboxane A_2 to be a significant biomarker of platelet activities. Platelet activities are multi-factorial in nature. Thromboxane A_2 reflects the recent activation of platelet which gives signals of potential haemorrhage. The action of thromboxane A_2 in autocrine and paracrine activities generate more thromboxane A_2 amplification as a platelet agonist. Thus, thromboxane A_2 is a potent platelet activator and vasoconstrictor that may have pathological consequences when activation is not balanced or controlled. Platelet activities of women on HAART should be studied, to assess the propensity to bleeding, especially during pregnancy.

CONFLICT OF INTERESTS

There is no conflict of interests.

Reference

- 1 Ademuyiwa, I. Y., Opeke, R.O, Farotimi, A.A, Ejidokun A, Olowe, A.O, and Ojo, E.A. (2021). Awareness and satisfaction with antenatal care services among pregnant women in Lagos state, Nigeria. *Calabar Journal of Health Science*, 5(1), 21-27.
- World Health Organization. (2016) *Standard for Maternal and Neonatal Care*. Geneva: World Health Organisation
- Sabina ,K. (2019). Prevalence of HIV Infection Among Pregnant Women Attending Ajiko Medical Clinic, Damaturu, Nigeria. *Journal of Clinical Research In HIV AIDS And Prevention*, 3(4), 7-9.
- Kefas, I.B., Envuladu, E. A., Miner, C., Pokop, B. W., Daboer, J.C., Chingle, M. P., Banwat, M. E. and Zoakah, A. I. (2021). Overall health-related quality of life of HIV infected and non-infected adult in Jos North Local Government Area, Plateau State. *Journal of Medicine in the Tropics*, 23 (1), 65-75.
- NACA (National Agency for the Control of AIDS). (2014). Global AIDS Response: Country Progress Report; Nigeria GARPR 2014. NACA.
- Kram, N.A., Yesufu, V., Lott, B., Breanne Lott, Kelly, N. B., Palmer, M. and Balogun, J.E. (2021). Making the most of our situation: a qualitative study reporting health providers' perspectives on the challenges of implementing the prevention of mother-to-child transmission of HIV services in Lagos, Nigeria. *Biomedical journal Open-2020* 046263.
- Atilola, G., Randle, T., Obadara, T., Komolafe, I. O., Odutolu, G., Olomu, J., and Adenuga, L. (2018). Epidemiology of HIV and Tuberculosis in pregnant women, South West Nigeria. *Journal of Infection and Public Health*, 11(6), 826-833.
- Zaba, B., Calvert, C., Marston, M., Isingo, R., Nakiyingi-Miir, J., Lutalo, T., Crampin, A., Robertson, L., Hervst, K., Newell, M., Todd, J., Byass, P., Boerma, T., and Ronsmans, C. (2013). Effect of HIV infection on pregnancy-related mortality in sub-Saharan Africa: secondary analyses of pooled community-based data from the network for analysing longitudinal population-based HIV/AIDS data on Africa (ALPHA). *Lancet*; 381(9879):1763-1771.
- Talargia, F., and Getacher, L (2021). Thrombocytopenia and Associated Factors among HIV Infected Patients in Pre- and Post-Anti-Retroviral Therapy, North East Ethiopia. *Journal of Blood Medicine*. 12:741-748
- Machlus, K. R., and Italiano, J. E. (2013). The incredible journey: From megakaryocyte development to platelet formation. *Journal of Cell Biology*, 201 (6), 785-796.
- Thon, J. N., Macleod, H., Begonja, A. J., Zhu, J., Lee, K. C., Mogilner, A., Hartwig, J. H., and Italiano, J. E., Jr (2012). Microtubule and cortical forces determine platelet size during vascular platelet production. *Nature communications*, 3, 852.
- Periayah, M. H., Halim, A. S., and Mat Saad, A. Z. (2017). Mechanism Action of Platelets and Crucial Blood Coagulation Pathways in Hemostasis. *International journal of hematology-oncology and stem cell research*, 11(4), 319-327.
- Grozovsky, R., Giannini, S., Falet, H., and Hoffmeister, K. M. (2015). Regulating billions of blood platelets: glycans and beyond. *Blood*, 126 (16), 1877-1884.
- Vox, S. (2018). The International Congress of the 35th Society of Blood Transfusion, Toronto. *The International Journal of Medicine*, 113 (S1), 345-347. doi:org/10.111/vox.12658.
- Rucker D., and Dhamoon A.S., (2022). Physiology, Thromboxane A2. In: StatPearls (Interne). Treasure Island (FL): StatPearls Publishing.
- Cognasse, F., Laradi, S., Berthelot, P., Bourlet, T., Marotte, H., Mismetti, P., Garraud, O., and Hamzeh-Cognasse, H. (2019). Platelet Inflammatory Response to Stress. *Frontiers in immunology*, 10, 1478.
- Hideki, A., Yoshiya, I., Koji, E., Shintaro, K., Fumihiko,

- O., Kanako, H., Kazuhito, O., Hideaki, T., Hiroyuki, S., Masabumi, S., Shuh, N., and Masataka, M. (2015). Thromboxane A₂ induces blood flow recovery via platelet adhesion to ischaemic regions, *Cardiovascular Research*, 107(4), 509–521.
- Jackson, B. S., Nunes Goncalves, J., and Pretorius, E. (2020). Comparison of pathological clotting using haematological, functional and morphological investigations in HIV-positive and HIV-negative patients with deep vein thrombosis. *Retrovirology*, 17(1), 14.
- Babaha, O. A., Oluwale, A. A., and Amaeshi, L. C. (2018). Platelet indices in healthy pregnant and non-pregnant Nigerian women. *Sub-Saharan African Journal of Medicine*, 5(4), 117-122.
- Tesfay, F., Negash, M., Alemu, J., Yahya, M., Teklu, G., Yibrah, M., Asfaw, T., and Tsegaye, A. (2019). Role of platelet parameters in early detection and prediction of severity of preeclampsia: A comparative cross-sectional study at Ayder comprehensive specialized and Mekelle general hospitals, Mekelle, Tigray, Ethiopia. *PloS one*, 14(11), e0225536.

How to cite this paper:

Olaniyi QF, Davies-Folorunsho TO, Ademosun AA¹, Abdulganiyu N, Omosigho OP, Olaniyan MF, Muhibi MA. Platelet activities in pregnant women living with Human Immunodeficiency Virus on HAART in Lagos, Nigeria. *Afr J Lab Haem Transf Sci* 2023; 2(1): 54-62.

This work is licensed under the Creative Commons Attribution (4.0) International License (CC BY 4.0) <https://creativecommons.org/licenses/by/4.0/>